Back
to sessions
Sep 29
Scientific
SS 41 - Optimizing Radiation Therapy in Gynecologic Cancers: Fractionation, Targeting, and Toxicity Reduction
MODERATOR(S)
Andrea Russo, MD - Massachusetts General Hospital/ Harvard Medical School
Shauna McVorran, MD, MHSA - University of Washington-Fred Hutchinson Cancer Center
Credits
| AMA PRA Category 1 Credits: | 1.25 |
Presentations
-
03:45pm - 03:55pm ET
Application Value of Whole-Process Individualized Intestinal Management in Radiotherapy for Gynecological Tumors: A Prospective Randomized Controlled Study
Speaker: Fei Bai, - radiotherapy department, xi,an -
03:55pm - 04:05pm ET
Hypofractionated IMRT and Weekly Cisplatin in Patients with Stage IIB and IIIB-C1 Cervix Cancer: A Phase I/II Study - The HYPOTHESIS Trial
Speaker: Heloisa de Andrade Carvalho, MD, PhD - University of São Paulo and Hospital Sírio-Libanês, Sao Paulo -
04:05pm - 04:15pm ET
Moderately Hypofractionated Online Adaptive Definitive Chemoradiotherapy for Cervical Cancer: Updated 2-Year Outcomes from a Prospective Institutional Study
Speaker: Zheng Zeng, MD - Peking Union Medical College Hospital, Beijing -
04:05pm - 04:15pm ET
Moderately Hypofractionated Online Adaptive Definitive Chemoradiotherapy for Cervical Cancer: Updated 2-Year Outcomes from a Prospective Institutional Study
Speaker: Zheng Zeng, MD - Peking Union Medical College Hospital, Beijing -
04:15pm - 04:25pm ET
MRI-Guided Pelvic Active Bone Marrow Sparing Intensity Modulated Radiotherapy Reduces the Incidence of the Hematologic Toxicity of Patients with Cervical Cancer: A Single-Center Prospective Randomized Controlled Trial
Speaker: Zixuan Yang, MS - the First Affiliated Hospital of Guangxi Medical University,, Nanning, Guangxi -
04:25pm - 04:35pm ET
Multi-Institutional Analysis of the Ideal Target Volume in MRI-Based Brachytherapy for Medically Inoperable Endometrial Cancer
Speaker: Isaac Lasko, MD - Loyola University Medical Center, Maywood -
04:35pm - 04:45pm ET
Quality-of-Life and Late Toxic Effects of Stereotactic Pelvic Adjuvant Radiation Therapy in Patients with Uterine Cancers: Update to the SPARTACUS Phase I/II Trial
Speaker: Eric Leung, MD - Sunnybrook Health Sciences Centre, Toronto -
04:45pm - 04:55pm ETSpeaker: Kevin Albuquerque, MD - Simmons Comprehensive Cancer Center, UTSW Radiation Oncology, Dallas